Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

IMJUDO

TREMELIMUMAB-ACTL

Standard Dose
300MG/15ML(20MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview IMJUDO is listed in Drugs@FDA under application 761289 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient TREMELIMUMAB-ACTL Form and strength INJECTABLE;INTRAVENOUS - 300MG/15ML(20MG/ML) Sponsor ASTRAZENECA AB Submission history Latest submission status date: 2024-07-24 00:00:00.

Structured Monograph

Clinical summary

Approval overview IMJUDO is listed in Drugs@FDA under application 761289 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient TREMELIMUMAB-ACTL Form and strength INJECTABLE;INTRAVENOUS - 300MG/15ML(20MG/ML) Sponsor ASTRAZENECA AB Submission history Latest submission status date: 2024-07-24 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.